Lurbinectedin (Zepzelca) for Small Cell Lung Cancer

The medically integrated pharmacy team is in a unique position to ensure appropriate treatment, increase compliance, and maximize outcomes. PQIs, an NCODA Quality Standard, are designed to operationalize and standardize those practices to achieve these positive clinical outcomes. PQIs are created, written, and updated biannually by NCODA members with expertise on the topic, making this a go-to for an up-to-date, relevant, patient-centered resource. Andrea Ketcham, PharmD of the McFarland Clinic shares, “the PQIs are very helpful. They give condensed, concise guidelines to work off.” This is echoed by Lawrence Garbo, MD of New York Oncology and Hematology, “PQIs provide an excellent overview that is easy to access and follow.” This PQI in Action will delve into Small Cell Lung Cancer (SCLC), the Lurbinectedin (ZEPZELCA™) for Small Cell Lung Cancer PQI, and three centers of excellence who have a passion for patients and excel at optimizing the patient experience.